Additionally, transcription factors such as FOXC1, which has been associated with the development of multiple tumors, TBX3, associated with Ulna-Mamma Syndrome, and TEAD1, linked to Neurofibroma and Spindle Cell Rhabdomyosarcoma, could be considered targets for drug repositioning. Here, TEAD1 is linked to neurofibroma.